CB Insights
Technology Market Intelligence
Technology Market Intelligence
NovMetaPharma (KONEX: 229500) is a pharmaceutical company focused on the development of new drugs for metabolic diseases. The company aims to introduce therapeutic agents for osteoporosis, non-alcoholic fatty liver disease, and immune system diseases...Show all
Company (IPO / Went public)
Phone: +82-2-538-1893
13F Trees Building
727 Eonju-ro, Gangnam-gu
Seoul, 06050
South Korea
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Pharmaceutical composition comprising amodiaquine and anti-diabetes drug as effective ingredient for prevention or treatment of diabetes | Aug 14, 2017 | Oct 06, 2020 | Patent |
| Novel polymorphic forms of cyclo (-his-pro) | Jun 21, 2019 | Jun 16, 2020 | Patent |
| Composition for preventing, alleviating or treating metabolic diseases, containing amodiaquine as active ingredient | Feb 16, 2016 | Jun 26, 2018 | Patent |
| Compositions and methods for treatment of atherosclerosis | Apr 30, 2019 | Application | |
| Composition comprising chp (cyclo-his pro) for preventing, improving or treating of bone loss related disease | Nov 20, 2018 | Application |
